Journal article icon

Journal article

Alemtuzumab (Campath-1H) in allogeneic stem cell transplantation: where do we go from here?

Abstract:

Alemtuzumab (Campath-1H) has been widely used for T-cell depletion following both conventional and reduced-intensity conditioning allografts. We studied the impact of alemtuzumab used in vivo and in vitro on infections, immune reconstitution, and allograft outcome. The use of alemtuzumab in vivo following reduced-intensity conditioning and unrelated donor conventional transplantation was associated with durable engraftment and significant reduction in graft-versus-host disease (GVHD) but at t...

Expand abstract
Publication status:
Published

Actions


Access Document


Authors


Chakrabarti, S More by this author
More by this author
Institution:
University of Oxford
Department:
Oxford, MSD, Pathology Dunn School
Journal:
Transplantation proceedings
Volume:
36
Issue:
5
Pages:
1225-1227
Publication date:
2004-06-05
DOI:
EISSN:
1873-2623
ISSN:
0041-1345
URN:
uuid:d2c17132-aef2-4c9b-b2d5-dbf51fdc5344
Source identifiers:
9804
Local pid:
pubs:9804

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP